Clinical Trials Browser

Phase 1 × capivasertib × Genitourinary × Clear all

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1 Completed

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)